Principal Investigator
Marijo Bilusic
Enrollment Status
Closed
Clinical Trial ID
Institutional Protocol #
20211217
Clinical Trial Summary
A Phase 2 Trial of SRF617 in Combination With AB928 (Etrumadenant) and AB122 (Zimberelimab) in Patients With Metastatic Castration-Resistant Prostate Cancer.
Phase
Phase II
Funding Agency/Sponsor
Industrial
Disease
Prostate, Bladder, and Kidney Cancers
Contact Information
Phone Number
305-243-2647